Abstract
Purpose: To establish whether first-order statistical features from [18F]fluoride and 2-deoxy-2-[F-18] fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) demonstrate incremental value in skeletal metastasis response assessment compared with maximum standardised uptake value (SUVmax).
Methods: Sixteen patients starting endocrine treatment for de-novo or progressive breast cancer bone metastases were prospectively recruited to undergo [18F]fluoride and [18F]FDG PET/CT scans before and 8 weeks after treatment. Percentage changes in SUV parameters, metabolic tumour volume (MTV), total lesion metabolism (TLM), standard deviation (SD), entropy, uniformity and absolute changes in kurtosis and skewness, from the same ≤ 5 index lesions, were measured. Clinical response to 24 weeks, assessed by 2 experienced oncologists blinded to PET/CT imaging findings, was used as a reference standard and associations were made between parameters and progression free and overall survival.
Results: [18F]fluoride PET/CT: In 4 patients (20 lesions) with progressive disease (PD), TLM and kurtosis predicted PD better than SUVmax on a patient basis (4,4,3 out of 4, respectively) and TLM, entropy, uniformity and skewness on a lesion basis (18,16,16,18,15 out of 20, respectively). Kurtosis was independently associated with PFS (p=0.033) and OS (p=0.008) on Kaplan-Meier analysis.
[18F]FDG PET: No parameter provided incremental value over SUVmax in predicting PD or non-PD. TLM was significantly associated with OS (p=0.041) and skewness with PFS (p=0.005).
Interlesional heterogeneity of response was seen in 11/16 and 8/16 patients on [18F]fluoride and [18F]FDG PET/CT, respectively.
Conclusion: With [18F]fluoride PET/CT some first-order features, including those that take into account lesion volume, but also some heterogeneity parameters, provide incremental value over SUVmax in predicting clinical response and survival in breast cancer patients with bone metastases treated with endocrine therapy. With [18F]FDG PET/CT, no first-order parameters were more accurate than SUVmax although TLM and skewness were associated with OS and PFS, respectively. Intra-patient heterogeneity of response occurs commonly between metastases with both tracers and most parameters.
Methods: Sixteen patients starting endocrine treatment for de-novo or progressive breast cancer bone metastases were prospectively recruited to undergo [18F]fluoride and [18F]FDG PET/CT scans before and 8 weeks after treatment. Percentage changes in SUV parameters, metabolic tumour volume (MTV), total lesion metabolism (TLM), standard deviation (SD), entropy, uniformity and absolute changes in kurtosis and skewness, from the same ≤ 5 index lesions, were measured. Clinical response to 24 weeks, assessed by 2 experienced oncologists blinded to PET/CT imaging findings, was used as a reference standard and associations were made between parameters and progression free and overall survival.
Results: [18F]fluoride PET/CT: In 4 patients (20 lesions) with progressive disease (PD), TLM and kurtosis predicted PD better than SUVmax on a patient basis (4,4,3 out of 4, respectively) and TLM, entropy, uniformity and skewness on a lesion basis (18,16,16,18,15 out of 20, respectively). Kurtosis was independently associated with PFS (p=0.033) and OS (p=0.008) on Kaplan-Meier analysis.
[18F]FDG PET: No parameter provided incremental value over SUVmax in predicting PD or non-PD. TLM was significantly associated with OS (p=0.041) and skewness with PFS (p=0.005).
Interlesional heterogeneity of response was seen in 11/16 and 8/16 patients on [18F]fluoride and [18F]FDG PET/CT, respectively.
Conclusion: With [18F]fluoride PET/CT some first-order features, including those that take into account lesion volume, but also some heterogeneity parameters, provide incremental value over SUVmax in predicting clinical response and survival in breast cancer patients with bone metastases treated with endocrine therapy. With [18F]FDG PET/CT, no first-order parameters were more accurate than SUVmax although TLM and skewness were associated with OS and PFS, respectively. Intra-patient heterogeneity of response occurs commonly between metastases with both tracers and most parameters.
| Original language | English |
|---|---|
| Journal | MOLECULAR IMAGING AND BIOLOGY |
| DOIs | |
| Publication status | Published - 24 Sept 2018 |
Keywords
- Breast cancer
- bone metastases
- Heterogeneity
- [18F]fluoride PET/CT
- [18F]FDG PET/CT
Access to Document
- Does Measurement of First-Order_AZAD_Firstonline24September2018_GOLD CP (CC BY)
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creative commons. org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.